Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06736990 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Calluna Pharma AS.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
20
Study locations

NCT06736990 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by Calluna Pharma AS. The registered enrollment target is 150 participants, below the 749-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06736990, a Phase 2 study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by Calluna Pharma AS.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.

Conditions Studied

Idiopathic Pulmonary Fibrosis

Interventions

  • DRUG Placebo
  • DRUG CAL101

Study Locations (20)

Other

  • Aarhus University Hospital - Aarhus
  • Rigshospitalet - Copenhagen
  • Odense University Hospital - Odense
  • AP-HP Hopital Avicenne - Bobigny
  • AP-HP Hopital Europeen Georges Pompidou - Paris
  • CHU Rennes - Hopital Pontchaillou - Rennes
  • CHU de Toulouse - Hopital Larrey - Toulouse
  • CHRU de Tours - Hôpital Bretonneau - Tours

North Carolina

  • Pulmonix, LLC - Greensboro
  • Southeastern Research Center - Winston-Salem

California

  • Keck School of Medicine at USC - Los Angeles

Colorado

  • National Jewish Health - Denver

Florida

  • Y & L Advance Health Care, Inc. d/b/a Elite Clinical Research - Miami

Kansas

  • University of Kansas Medical Center - Kansas City

Ohio

  • Cleveland Clinic - Cleveland

Pennsylvania

  • Temple University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-06-20
Est. Completion 2027-11
Phase Phase 2

Sponsor

Calluna Pharma AS

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06736990

The ClinicalTrials.gov registry entry for NCT06736990 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 749-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (80% lower). The listed sponsor is Calluna Pharma AS, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06736990 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, North Carolina, California.

Frequently Asked Questions

What is clinical trial NCT06736990 about?

NCT06736990 is a clinical study titled "A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis". The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants w...

What is the current status of trial NCT06736990?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-06-20. Estimated completion is 2027-11.

What conditions does trial NCT06736990 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.

What interventions are being tested in trial NCT06736990?

The interventions under investigation include: Placebo (DRUG), CAL101 (DRUG).

Who is sponsoring clinical trial NCT06736990?

This trial is sponsored by Calluna Pharma AS, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06736990 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Kansas, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Pulmonary Fibrosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.